A novel VIM-type metallo-β-lactamase variant, VIM-60, was identified in multidrug-resistant clinical isolates in Japan. Compared with VIM-2, VIM-60 had two amino acid substitutions (Arg228Leu and His252Arg) and higher catalytic activities against fourth-generation cephalosporins. The genetic context for was - on the chromosome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535569 | PMC |
| http://dx.doi.org/10.1128/AAC.00124-19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genome characteristics of an MDR Pseudomonas monteilii carrying a novel VIM-type β-lactamase, bla.
J Glob Antimicrob Resist
December 2024
Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, China. Electronic address:
Article Synopsis
- The study aimed to identify and characterize a novel VIM-type β-lactamase (VIM-84) found in a multidrug-resistant strain of Pseudomonas monteilii isolated from the human gut through whole-genome sequencing.
- DNA extraction and sequencing were conducted using advanced technology, and the transmissibility of resistance genes was tested on specific culture plates, confirming the bacteria’s genetic makeup and resistance genes on both the chromosome and plasmid.
- The findings indicate that Pseudomonas monteilii can harbor resistance genes and may act as a reservoir for these genes, which were previously thought to be primarily associated with Pseudomonas aeruginosa.
VIM-type metallo-β-lactamase (MBL)-encoding genomic islands in Pseudomonas spp. in Poland: predominance of clc-like integrative and conjugative elements (ICEs).
J Antimicrob Chemother
May 2024
Department of Molecular Microbiology, National Medicines Institute, Chełmska 30/34, Warsaw 00-725, Poland.
Objectives: To characterize VIM-type metallo-β-lactamase (MBL)-encoding genomic islands (GIs) in Pseudomonas aeruginosa and P. putida group isolates from Polish hospitals from 2001-2015/16.
Methods: Twelve P.
Characterization of VIM-71, a novel VIM-type metallo-β-lactamase variant encoded by an integrative and conjugative element recovered from a Vibrio alginolyticus strain in China.
Microbiol Res
January 2024
The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, PR China; State Key Lab for Chemical Biology and Drug Discovery, and the Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. Electronic address:
Article Synopsis
- A new variant of metallo-β-lactamase, named VIM-71, was discovered in a multidrug-resistant Vibrio alginolyticus strain from a shrimp sample in China.
- VIM-71 differs from the previously known VIM-1 in 22 amino acid positions and has similar resistance to penicillins, but offers lower resistance to carbapenems compared to VIM-1.
- The gene responsible for this resistance (bla) is located in a specific genetic element within the bacterium's chromosome, suggesting ongoing evolution of resistance in Vibrio species.
Characterization of two novel VIM-type metallo-β-lactamases, VIM-84 and VIM-85, associated with the spread of IncP-2 megaplasmids in .
Microbiol Spectr
September 2023
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Article Synopsis
- This study identifies two new metallo-β-lactamases, VIM-84 and VIM-85, which contribute to antimicrobial resistance (AMR) spread through IncP-2 type megaplasmids.
- Both enzymes are encoded by novel genes found within class 1 integrons and exhibit stronger resistance to β-lactams compared to an existing enzyme, VIM-24.
- The research highlights the global distribution of these megaplasmids and their role in facilitating hospital outbreaks by harboring and disseminating AMR genes.
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
J Chemother
May 2023
Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.
This study was aimed at analyzing the prevalence of metallo-β-lactamase-producing Gram-negative bacilli (MBL-GNB) and evaluating both activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations. Carbapenemase-producing Enterobacterales and meropenem-non-susceptible clinical strains were collected (2019-2020) and prevalence of MBL-producers investigated. Activity of cefiderocol was evaluated and synergistic effects of cefiderocol in combination with ceftazidime/avibactam aztreonam plus ceftazidime/avibactam meropenem/vaborbactam plus aztreonam were compared.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!